newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in